mesalamine has been researched along with Breast Cancer in 4 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| " One comparing two different dosing regimens for the maintenance of remission in people with ulcerative colitis (CODA), and the other comparing an orally administered treatment to an intravenously administered treatment in preventing skeletal-related events in patients with bone metastases from breast cancer (ZICE)." | 1.46 | The use of randomisation-based efficacy estimators in non-inferiority trials. ( Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R, 2017) |
| "Azathioprine (AZA) treatment in transplant or autoimmune patients and subsequent appearance squamous cell carcinomas at various sites, particularly skin and cervix, has shown a close relationship." | 1.38 | [A case of squamous cell carcinoma of the breast in a patient with Crohn's disease taking azathioprine]. ( Cho, JY; Heo, SW; Ju, DU; Kim, EJ; Kim, EY; Oh, HK; Park, KC; Ryu, JI, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moreno Moraleda, I | 1 |
| Lázaro Sáez, M | 1 |
| Diéguez Castillo, C | 1 |
| Hernández Martínez, Á | 1 |
| Gillespie, D | 1 |
| Farewell, D | 1 |
| Barrett-Lee, P | 1 |
| Casbard, A | 1 |
| Hawthorne, AB | 1 |
| Hurt, C | 1 |
| Murray, N | 1 |
| Probert, C | 1 |
| Stenson, R | 1 |
| Hood, K | 1 |
| Park, KC | 1 |
| Ju, DU | 1 |
| Heo, SW | 1 |
| Ryu, JI | 1 |
| Cho, JY | 1 |
| Kim, EJ | 1 |
| Oh, HK | 1 |
| Kim, EY | 1 |
| Schwetz, BA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate [NCT00326820] | Phase 3 | 1,404 participants (Actual) | Interventional | 2006-01-31 | Active, not recruiting | ||
| A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.[NCT00708656] | Phase 3 | 213 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for mesalamine and Breast Cancer
| Article | Year |
|---|---|
Inflammatory bowel disease and inherited colorectal cancer: Is there a genetic link?
Topics: Adenocarcinoma; Adult; Age of Onset; Anti-Inflammatory Agents; Azathioprine; Breast Neoplasms; Colit | 2021 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
[A case of squamous cell carcinoma of the breast in a patient with Crohn's disease taking azathioprine].
Topics: Adult; Azathioprine; Breast Neoplasms; Carcinoma, Squamous Cell; Colonoscopy; Combined Modality Ther | 2012 |
From the Food and Drug Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 2001 |